Tiagabine Quantitative, Serum/Plasma
Also known as: TIAGAB SP
Use
Tiagabine Quantitative, Serum/Plasma test is used primarily for therapeutic drug monitoring to optimize drug therapy and monitor patient adherence. This test measures the concentration of Tiagabine, an anticonvulsant, in serum or plasma samples. The results are used to ensure that drug levels remain within a therapeutic range, as the relationship between plasma concentrations and clinical response is not fully understood. Trough plasma concentrations from 1-234 ng/mL have been reported in clinical studies at doses of 30-56 mg per day.
Special Instructions
Not provided.
Limitations
The relationship between Tiagabine plasma concentrations and the clinical response is not currently understood. A diurnal effect on Tiagabine pharmacokinetics has been noted, with mean steady-state trough concentrations lower in the evening than in the morning. As the test is performed by NMS Labs, it has not been cleared or approved by the US Food and Drug Administration, and performance characteristics are determined by NMS Labs only.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
Tiagabine
Analyte
LOINC Codes
- 21565-7 - tiaGABine SerPl-mCnc
Result Turnaround Time
8-11 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.4 mL
Container
ARUP Standard Transport Tube (Plain Red, Lavender (EDTA), or Pink (K2EDTA)).
Collection Instructions
Separate from cells ASAP or within 2 hours of collection and transfer to an ARUP Standard Transport Tube.
Patient Preparation
Pre-dose (trough) draw required.
Causes for Rejection
Separator tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 month |
| Refrigerated | 1 month |
| Frozen | 48 months |
Other tests from different labs that may be relevant